Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 23, 2018 14:00 ET | Source: KemPharm

KemPharm Announces FDA Approval of Apadaz™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain

Apadaz is the First Prodrug of Hydrocodone/Acetaminophen to be Approved by FDA Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 2:30 p.m. ET CORALVILLE, Iowa,...
February 13, 2018 07:30 ET | Source: KemPharm

KemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference

Corporate Updates and Clinical Progress to be Highlighted CORALVILLE, Iowa, Feb. 13, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company...
January 31, 2018 07:30 ET | Source: KemPharm

KemPharm to Present at The MoneyShow Orlando Investor Conference

CORALVILLE, Iowa, Jan. 31, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,...
January 23, 2018 07:30 ET | Source: KemPharm

KemPharm Receives Patent Grant for KP606, a Prodrug of Oxycodone

Additional Patent Granted for the KP511-related family, a Prodrug of Hydromorphone CORALVILLE, Iowa, Jan. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty...
January 08, 2018 07:30 ET | Source: KemPharm

KemPharm Initiates Pivotal Efficacy Trial of KP415

‘Classroom-style’ Pivotal Efficacy Trial of ADHD Prodrug Composition Candidate to Study Onset and Duration of Efficacy and Product Safety Screening commenced in November; first patient treatment...
November 16, 2017 07:30 ET | Source: KemPharm

KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA

All Clinical and Non-Clinical Programs Remain on Track for ADHD Prodrug Candidate, Pivotal Efficacy Trial to Study Duration of Therapy to Initiate Prior to Year-End CORALVILLE, Iowa, Nov. 16, 2017 ...
November 09, 2017 16:05 ET | Source: KemPharm

KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Filed IND for KP484, A Super-Extended Release ADHD...
November 06, 2017 07:30 ET | Source: KemPharm

KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511

CORALVILLE, Iowa, Nov. 06, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc, a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today...
November 02, 2017 07:30 ET | Source: KemPharm

KemPharm’s KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies

KP484 Designed to be a Predictably Dosed, “Super-Extended” Release, Methylphenidate Product Candidate CORALVILLE, Iowa, Nov. 02, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc, a clinical-stage...
November 01, 2017 16:30 ET | Source: KemPharm

KemPharm, Inc. to Report Third Quarter 2017 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for November 9, 2017, 4:30 p.m. ET CORALVILLE, Iowa, Nov. 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a...